Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine
Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with...
Gespeichert in:
| Veröffentlicht in: | Rheumatology international 2022-06, Vol.42 (6), p.973-987 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 987 |
|---|---|
| container_issue | 6 |
| container_start_page | 973 |
| container_title | Rheumatology international |
| container_volume | 42 |
| creator | Ozdede, Ayse Guner, Sabriye Ozcifci, Guzin Yurttas, Berna Toker Dincer, Zeynep Atli, Zeynep Uygunoğlu, Uğur Durmaz, Eser Uçar, Didar Uğurlu, Serdal Saip, Sabahattin Tabak, Fehmi Hamuryudan, Vedat Seyahi, Emire |
| description | Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with CoronaVac (BS:109, FMF: 90, and RD: 343,) or BioNTech (BS: 147, FMF: 157 and RD: 258). The majority have received double dose (BS: 94.9%, FMF 92.3% and RD: 86.2%). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%; FMF: 3.2% vs 12.2%, RD:2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; and RD: 83.3% vs 45.5%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS: 5.5%, FMF: 3.3%, and RD:2.9%) or BioNTech (BS: 5.4%, FMF: 1.9%, and RD: 4.7%). The main causes for medical assistance were disease flare and cardiovascular events. Patients with BS (16.0%) and FMF (17.4%) were found to flare significantly more frequently when compared to those with RD (6.0%) (
p
|
| doi_str_mv | 10.1007/s00296-022-05119-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8977433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2646945210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-9f3d7cc0bddcd61a7019d3a0cb8fa1fcadbe75dddd38c89108326187d534c4993</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIREvhBVggS2zYGPwzsWdYIIWIP6kFqQHEznLs68bVjJ3aTlB2vAaPw6vwJDhNKYUF3tiWv3vu8dVpmoeUPKWEyGeZENYLTBjDZEJpj7e3mkPacompIF9u3zgfNPdyPieESiHI3eaAT7gUvWCHzY-5dlC2KDo0n57O8Sx-xgxttDE-6OJjQD6gVT1BKBl99WWJXsLSQPn57XtGeRtsiiMgHSxyevSD1wM6AesLpKQD6IAcbCA9RxqZFHPGGcxOtmImjiudqvQGUC5rW00EVJaAwLkK5Z2nE3z6fooWOoO97FFN1fKNLvW-Nwn3mztODxkeXO1HzafXrz7O3uLjD2_ezabH2LSkLbh33EpjyMJaYwXVktDeck3MonOaOqPtAuTE1sU70_WUdJwJ2kk74a1p-54fNS_2uqv1YgRr6kCSHtQq-VGnrYraq79fgl-qs7hRXS9ly3kVeHIlkOLFGnJRo88GhqHOKa6zYqIVfTthlFT08T_oeVynOrQdJaRgrOU7iu2py8kmcNdmKFG7hKh9QlRNiLpMiNrWokc3v3Fd8jsSFeB7INencAbpT-__yP4CsRzM6A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2667622430</pqid></control><display><type>article</type><title>Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ozdede, Ayse ; Guner, Sabriye ; Ozcifci, Guzin ; Yurttas, Berna ; Toker Dincer, Zeynep ; Atli, Zeynep ; Uygunoğlu, Uğur ; Durmaz, Eser ; Uçar, Didar ; Uğurlu, Serdal ; Saip, Sabahattin ; Tabak, Fehmi ; Hamuryudan, Vedat ; Seyahi, Emire</creator><creatorcontrib>Ozdede, Ayse ; Guner, Sabriye ; Ozcifci, Guzin ; Yurttas, Berna ; Toker Dincer, Zeynep ; Atli, Zeynep ; Uygunoğlu, Uğur ; Durmaz, Eser ; Uçar, Didar ; Uğurlu, Serdal ; Saip, Sabahattin ; Tabak, Fehmi ; Hamuryudan, Vedat ; Seyahi, Emire</creatorcontrib><description>Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with CoronaVac (BS:109, FMF: 90, and RD: 343,) or BioNTech (BS: 147, FMF: 157 and RD: 258). The majority have received double dose (BS: 94.9%, FMF 92.3% and RD: 86.2%). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%; FMF: 3.2% vs 12.2%, RD:2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; and RD: 83.3% vs 45.5%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS: 5.5%, FMF: 3.3%, and RD:2.9%) or BioNTech (BS: 5.4%, FMF: 1.9%, and RD: 4.7%). The main causes for medical assistance were disease flare and cardiovascular events. Patients with BS (16.0%) and FMF (17.4%) were found to flare significantly more frequently when compared to those with RD (6.0%) (
p
< 0.001). This was true for either vaccine. BS patients reported mainly skin-mucosa lesions; there were however, 11 (4.3%) who developed major organ attack such as uveitis, thrombosis or stroke. Flare in FMF patients were associated mainly with acute serositis with or without fever. Arthralgia/arthritis or inflammatory back pain were observed mainly in the RD group. Our study demonstrates that BS and FMF patients vaccinated with either CoronaVac or BioNTech demonstrated similar AE profile and frequency compared to RD patients. AEs that required physician consultation or hospitalization occurred in all study groups after either CoronaVac or BioNTech. Increased frequency of flares in BS and FMF compared to that seen in RD might reflect defects in innate immunity and deserves further investigation. Caution should be required when monitoring these patients after vaccination.</description><identifier>ISSN: 1437-160X</identifier><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-022-05119-y</identifier><identifier>PMID: 35376962</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Behcet Syndrome - complications ; Coronaviruses ; COVID-19 - prevention & control ; COVID-19 vaccines ; COVID-19 Vaccines - adverse effects ; Cross-Sectional Studies ; Familial Mediterranean Fever - complications ; Fever ; Humans ; Medicine ; Medicine & Public Health ; Observational Research ; Pain - complications ; Rheumatic Diseases - complications ; Rheumatology ; RNA ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination - adverse effects ; Vaccines, Inactivated ; Vein & artery diseases</subject><ispartof>Rheumatology international, 2022-06, Vol.42 (6), p.973-987</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-9f3d7cc0bddcd61a7019d3a0cb8fa1fcadbe75dddd38c89108326187d534c4993</citedby><cites>FETCH-LOGICAL-c404t-9f3d7cc0bddcd61a7019d3a0cb8fa1fcadbe75dddd38c89108326187d534c4993</cites><orcidid>0000-0002-9561-2282 ; 0000-0002-9582-8374 ; 0000-0002-2802-7227 ; 0000-0002-6531-8138 ; 0000-0002-1468-0153 ; 0000-0002-2959-0978 ; 0000-0002-6096-0340 ; 0000-0002-4774-9284 ; 0000-0003-4965-2918 ; 0000-0003-2866-4004 ; 0000-0001-6625-1652 ; 0000-0002-0762-7725 ; 0000-0001-8632-2825 ; 0000-0002-3469-7307</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00296-022-05119-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00296-022-05119-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35376962$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ozdede, Ayse</creatorcontrib><creatorcontrib>Guner, Sabriye</creatorcontrib><creatorcontrib>Ozcifci, Guzin</creatorcontrib><creatorcontrib>Yurttas, Berna</creatorcontrib><creatorcontrib>Toker Dincer, Zeynep</creatorcontrib><creatorcontrib>Atli, Zeynep</creatorcontrib><creatorcontrib>Uygunoğlu, Uğur</creatorcontrib><creatorcontrib>Durmaz, Eser</creatorcontrib><creatorcontrib>Uçar, Didar</creatorcontrib><creatorcontrib>Uğurlu, Serdal</creatorcontrib><creatorcontrib>Saip, Sabahattin</creatorcontrib><creatorcontrib>Tabak, Fehmi</creatorcontrib><creatorcontrib>Hamuryudan, Vedat</creatorcontrib><creatorcontrib>Seyahi, Emire</creatorcontrib><title>Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with CoronaVac (BS:109, FMF: 90, and RD: 343,) or BioNTech (BS: 147, FMF: 157 and RD: 258). The majority have received double dose (BS: 94.9%, FMF 92.3% and RD: 86.2%). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%; FMF: 3.2% vs 12.2%, RD:2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; and RD: 83.3% vs 45.5%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS: 5.5%, FMF: 3.3%, and RD:2.9%) or BioNTech (BS: 5.4%, FMF: 1.9%, and RD: 4.7%). The main causes for medical assistance were disease flare and cardiovascular events. Patients with BS (16.0%) and FMF (17.4%) were found to flare significantly more frequently when compared to those with RD (6.0%) (
p
< 0.001). This was true for either vaccine. BS patients reported mainly skin-mucosa lesions; there were however, 11 (4.3%) who developed major organ attack such as uveitis, thrombosis or stroke. Flare in FMF patients were associated mainly with acute serositis with or without fever. Arthralgia/arthritis or inflammatory back pain were observed mainly in the RD group. Our study demonstrates that BS and FMF patients vaccinated with either CoronaVac or BioNTech demonstrated similar AE profile and frequency compared to RD patients. AEs that required physician consultation or hospitalization occurred in all study groups after either CoronaVac or BioNTech. Increased frequency of flares in BS and FMF compared to that seen in RD might reflect defects in innate immunity and deserves further investigation. Caution should be required when monitoring these patients after vaccination.</description><subject>Behcet Syndrome - complications</subject><subject>Coronaviruses</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>COVID-19 Vaccines - adverse effects</subject><subject>Cross-Sectional Studies</subject><subject>Familial Mediterranean Fever - complications</subject><subject>Fever</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Observational Research</subject><subject>Pain - complications</subject><subject>Rheumatic Diseases - complications</subject><subject>Rheumatology</subject><subject>RNA</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination - adverse effects</subject><subject>Vaccines, Inactivated</subject><subject>Vein & artery diseases</subject><issn>1437-160X</issn><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9ks1uEzEUhUcIREvhBVggS2zYGPwzsWdYIIWIP6kFqQHEznLs68bVjJ3aTlB2vAaPw6vwJDhNKYUF3tiWv3vu8dVpmoeUPKWEyGeZENYLTBjDZEJpj7e3mkPacompIF9u3zgfNPdyPieESiHI3eaAT7gUvWCHzY-5dlC2KDo0n57O8Sx-xgxttDE-6OJjQD6gVT1BKBl99WWJXsLSQPn57XtGeRtsiiMgHSxyevSD1wM6AesLpKQD6IAcbCA9RxqZFHPGGcxOtmImjiudqvQGUC5rW00EVJaAwLkK5Z2nE3z6fooWOoO97FFN1fKNLvW-Nwn3mztODxkeXO1HzafXrz7O3uLjD2_ezabH2LSkLbh33EpjyMJaYwXVktDeck3MonOaOqPtAuTE1sU70_WUdJwJ2kk74a1p-54fNS_2uqv1YgRr6kCSHtQq-VGnrYraq79fgl-qs7hRXS9ly3kVeHIlkOLFGnJRo88GhqHOKa6zYqIVfTthlFT08T_oeVynOrQdJaRgrOU7iu2py8kmcNdmKFG7hKh9QlRNiLpMiNrWokc3v3Fd8jsSFeB7INencAbpT-__yP4CsRzM6A</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Ozdede, Ayse</creator><creator>Guner, Sabriye</creator><creator>Ozcifci, Guzin</creator><creator>Yurttas, Berna</creator><creator>Toker Dincer, Zeynep</creator><creator>Atli, Zeynep</creator><creator>Uygunoğlu, Uğur</creator><creator>Durmaz, Eser</creator><creator>Uçar, Didar</creator><creator>Uğurlu, Serdal</creator><creator>Saip, Sabahattin</creator><creator>Tabak, Fehmi</creator><creator>Hamuryudan, Vedat</creator><creator>Seyahi, Emire</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9561-2282</orcidid><orcidid>https://orcid.org/0000-0002-9582-8374</orcidid><orcidid>https://orcid.org/0000-0002-2802-7227</orcidid><orcidid>https://orcid.org/0000-0002-6531-8138</orcidid><orcidid>https://orcid.org/0000-0002-1468-0153</orcidid><orcidid>https://orcid.org/0000-0002-2959-0978</orcidid><orcidid>https://orcid.org/0000-0002-6096-0340</orcidid><orcidid>https://orcid.org/0000-0002-4774-9284</orcidid><orcidid>https://orcid.org/0000-0003-4965-2918</orcidid><orcidid>https://orcid.org/0000-0003-2866-4004</orcidid><orcidid>https://orcid.org/0000-0001-6625-1652</orcidid><orcidid>https://orcid.org/0000-0002-0762-7725</orcidid><orcidid>https://orcid.org/0000-0001-8632-2825</orcidid><orcidid>https://orcid.org/0000-0002-3469-7307</orcidid></search><sort><creationdate>20220601</creationdate><title>Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine</title><author>Ozdede, Ayse ; Guner, Sabriye ; Ozcifci, Guzin ; Yurttas, Berna ; Toker Dincer, Zeynep ; Atli, Zeynep ; Uygunoğlu, Uğur ; Durmaz, Eser ; Uçar, Didar ; Uğurlu, Serdal ; Saip, Sabahattin ; Tabak, Fehmi ; Hamuryudan, Vedat ; Seyahi, Emire</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-9f3d7cc0bddcd61a7019d3a0cb8fa1fcadbe75dddd38c89108326187d534c4993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Behcet Syndrome - complications</topic><topic>Coronaviruses</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>COVID-19 Vaccines - adverse effects</topic><topic>Cross-Sectional Studies</topic><topic>Familial Mediterranean Fever - complications</topic><topic>Fever</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Observational Research</topic><topic>Pain - complications</topic><topic>Rheumatic Diseases - complications</topic><topic>Rheumatology</topic><topic>RNA</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination - adverse effects</topic><topic>Vaccines, Inactivated</topic><topic>Vein & artery diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ozdede, Ayse</creatorcontrib><creatorcontrib>Guner, Sabriye</creatorcontrib><creatorcontrib>Ozcifci, Guzin</creatorcontrib><creatorcontrib>Yurttas, Berna</creatorcontrib><creatorcontrib>Toker Dincer, Zeynep</creatorcontrib><creatorcontrib>Atli, Zeynep</creatorcontrib><creatorcontrib>Uygunoğlu, Uğur</creatorcontrib><creatorcontrib>Durmaz, Eser</creatorcontrib><creatorcontrib>Uçar, Didar</creatorcontrib><creatorcontrib>Uğurlu, Serdal</creatorcontrib><creatorcontrib>Saip, Sabahattin</creatorcontrib><creatorcontrib>Tabak, Fehmi</creatorcontrib><creatorcontrib>Hamuryudan, Vedat</creatorcontrib><creatorcontrib>Seyahi, Emire</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ozdede, Ayse</au><au>Guner, Sabriye</au><au>Ozcifci, Guzin</au><au>Yurttas, Berna</au><au>Toker Dincer, Zeynep</au><au>Atli, Zeynep</au><au>Uygunoğlu, Uğur</au><au>Durmaz, Eser</au><au>Uçar, Didar</au><au>Uğurlu, Serdal</au><au>Saip, Sabahattin</au><au>Tabak, Fehmi</au><au>Hamuryudan, Vedat</au><au>Seyahi, Emire</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>42</volume><issue>6</issue><spage>973</spage><epage>987</epage><pages>973-987</pages><issn>1437-160X</issn><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet’s syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effects and disease flares after COVID-19 vaccination with either Pfizer/BioNTech or Sinovac/CoronaVac in 256 patients with BS, 247 with FMF, and 601 with RD. Telephone interviews were conducted using a questionnaire survey in a cross-sectional design in patients with BS, FMF, and RD followed by a single university hospital. Study participants were vaccinated either with CoronaVac (BS:109, FMF: 90, and RD: 343,) or BioNTech (BS: 147, FMF: 157 and RD: 258). The majority have received double dose (BS: 94.9%, FMF 92.3% and RD: 86.2%). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%; FMF: 3.2% vs 12.2%, RD:2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; and RD: 83.3% vs 45.5%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS: 5.5%, FMF: 3.3%, and RD:2.9%) or BioNTech (BS: 5.4%, FMF: 1.9%, and RD: 4.7%). The main causes for medical assistance were disease flare and cardiovascular events. Patients with BS (16.0%) and FMF (17.4%) were found to flare significantly more frequently when compared to those with RD (6.0%) (
p
< 0.001). This was true for either vaccine. BS patients reported mainly skin-mucosa lesions; there were however, 11 (4.3%) who developed major organ attack such as uveitis, thrombosis or stroke. Flare in FMF patients were associated mainly with acute serositis with or without fever. Arthralgia/arthritis or inflammatory back pain were observed mainly in the RD group. Our study demonstrates that BS and FMF patients vaccinated with either CoronaVac or BioNTech demonstrated similar AE profile and frequency compared to RD patients. AEs that required physician consultation or hospitalization occurred in all study groups after either CoronaVac or BioNTech. Increased frequency of flares in BS and FMF compared to that seen in RD might reflect defects in innate immunity and deserves further investigation. Caution should be required when monitoring these patients after vaccination.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35376962</pmid><doi>10.1007/s00296-022-05119-y</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-9561-2282</orcidid><orcidid>https://orcid.org/0000-0002-9582-8374</orcidid><orcidid>https://orcid.org/0000-0002-2802-7227</orcidid><orcidid>https://orcid.org/0000-0002-6531-8138</orcidid><orcidid>https://orcid.org/0000-0002-1468-0153</orcidid><orcidid>https://orcid.org/0000-0002-2959-0978</orcidid><orcidid>https://orcid.org/0000-0002-6096-0340</orcidid><orcidid>https://orcid.org/0000-0002-4774-9284</orcidid><orcidid>https://orcid.org/0000-0003-4965-2918</orcidid><orcidid>https://orcid.org/0000-0003-2866-4004</orcidid><orcidid>https://orcid.org/0000-0001-6625-1652</orcidid><orcidid>https://orcid.org/0000-0002-0762-7725</orcidid><orcidid>https://orcid.org/0000-0001-8632-2825</orcidid><orcidid>https://orcid.org/0000-0002-3469-7307</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1437-160X |
| ispartof | Rheumatology international, 2022-06, Vol.42 (6), p.973-987 |
| issn | 1437-160X 0172-8172 1437-160X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8977433 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Behcet Syndrome - complications Coronaviruses COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects Cross-Sectional Studies Familial Mediterranean Fever - complications Fever Humans Medicine Medicine & Public Health Observational Research Pain - complications Rheumatic Diseases - complications Rheumatology RNA SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccination - adverse effects Vaccines, Inactivated Vein & artery diseases |
| title | Safety of SARS-CoV-2 vaccination in patients with Behcet’s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A12%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20SARS-CoV-2%20vaccination%20in%20patients%20with%20Behcet%E2%80%99s%20syndrome%20and%20familial%20Mediterranean%20fever:%20a%20cross-sectional%20comparative%20study%20on%20the%20effects%20of%20M-RNA%20based%20and%20inactivated%20vaccine&rft.jtitle=Rheumatology%20international&rft.au=Ozdede,%20Ayse&rft.date=2022-06-01&rft.volume=42&rft.issue=6&rft.spage=973&rft.epage=987&rft.pages=973-987&rft.issn=1437-160X&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-022-05119-y&rft_dat=%3Cproquest_pubme%3E2646945210%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2667622430&rft_id=info:pmid/35376962&rfr_iscdi=true |